(CercleFinance.com) – Theradiag, a specialist in in vitro diagnostics, rose by more than 2% this Monday on the Paris Stock Exchange following the publication of first half results showing a strong improvement in its profitability.
The specialist in ‘theranostics’, a discipline on the borders of treatment and diagnosis, achieved a ‘record’ operating result of 835,000 euros over the first six months of the year, or an operating margin of 12.5%.
The group, whose tests make it possible to measure the effectiveness of biotherapies in the treatment of chronic diseases, explains that it has benefited from the optimization of the management of its operational costs, mainly due to the cessation of activities in the United States.
Its half-year turnover stood at 6.7 million euros compared to 6.3 million in the first half of 2022, an increase of 7%.
As of June 30, its net available cash amounted to 5.7 million euros, an increase compared to the end of March and above the company’s business plan.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information on THERADIAG in real time: